IGF-1R: a validated thyroid eye disease target and a re-emerging cancer target – a pipeline review STUTTGART, Germany I September 05, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-IGF-1(R) immunotherapies in R&D: Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy....

NaPi2b: a viable solid tumor target for novel ADC technologies – a pipeline review STUTTGART, Germany I September 04, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-NaPi2b immunotherapies in R&D: Pipeline of NaPi2b-Targeted Immunotherapies. This competitive intelligence report about...

FcRn: a commercially and clinically validated target in a variety of antibody-mediated autoimmune diseases – a pipeline review STUTTGART, Germany I September 03, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-FcRn therapeutics in R&D: Pipeline of FcRn-Targeted Therapies. This...

New service: competitor analysis of targeted immunotherapies with targets selected by clients STUTTGART, Germany I September 01, 2025 I La Merie Publishing announced the launch of its newest service offering of reviewing the pipeline of immunotherapeutics for targets selected by clients: Pipeline Review of Customer-Selected Targeted Immunotherapies: Pre-Scoped Competitor Analysis....

KLK2: promising drug target in prostate cancer – a pipeline review STUTTGART, Germany I August 31, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-KLK2 immunotherapeutics in R&D: Pipeline of KLK2-Targeted Immunotherapies. This competitive intelligence report about Pipeline of KLK2-Targeted...

Vectorized antibodies by in vivo expression of DNA or RNA overcome limitations of systemically administered antibodies STUTTGART, Germany I August 30, 2025 I Antibodies as a drug modality in general have become extremely successful in terms of clinically effective therapies and of market size. The global market size of all...

STEAP1 and STEAP2: emerging prostate cancer targets – a pipeline review STUTTGART, Germany I August 30, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-STEAP1- and/or STEAP2 immunotherapeutics in R&D: Pipeline of STEAP1- and STEAP2-Targeted Immunotherapies. This competitive intelligence report...

Tissue Factor: a validated target for improved solid tumor antibody-drug conjugates – a pipeline review STUTTGART, Germany I August 27, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-Tissue Factor immunotherapeutics in R&D: Pipeline of Tissue Factor-Targeted Immunotherapies. This competitive...

CD38: a Blockbuster sales target under fire by biosuperior and biosmilar antibody competitors – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-CD38 immunotherapeutics in R&D: Pipeline of CD38-Targeted Immunotherapies. This competitive...

TROP-2: a Blockbuster target with opportunities for new drug modalities – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-TROP-2 immunotherapeutics in R&D: Pipeline of TROP-2-Targeted Immunotherapies. This competitive intelligence report about...